MPOX
12
3
6
3
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 42/100
8.3%
1 terminated out of 12 trials
75.0%
-11.5% vs benchmark
33%
4 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (12)
Study of Tecovirimat for Human Mpox Virus
Mpox Biology, Outcome, Transmission and Epidemiology - Tracking the Immune Response After mpoX vaCcination (MBOTE-TRAXX): Clinical Study to Monitor the Immunological Response Following Mpox Vaccination in the City of Kinshasa, Democratic Republic of the Congo
Validation of SDS-EDTA-Treated Chromatography Paper Strips for Mpox Sampling and Transport in DRC
Assessment of the Efficacy and Safety of Tecovirimat in Patients With Monkeypox Virus Disease
Phase 3 Maternal Safety & Immunogenicity Trial of MVA-BN® in DRC
New York City Observational Study of Mpox Immunity
Evaluation of Effectiveness and Safety of LC16m8 Mpox Vaccine in the Democratic Republic of Congo (DRC)
A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From ≥18 Years of Age to <50 Years of Age
Monkeypox, Biology, Outcome, Transmission and Epidemiology -Prospective Follow-up of High-risk Contacts
Mpox Comprehensive Assessment for Responsive Immunisation in Emergency Outbreaks
Observational, Prospective, Cohort Study of Mpox Infection in Brazil (NETPOX)
Break-through Infection Following Mpox vaccinatIon